• White Facebook Icon
  • White LinkedIn Icon
  • White Twitter Icon

Artificial Intelligence for Drug Discovery Landscape Overview

Q2 / 2018 Industry Analysis

Section I: AI for Drug Discovery Landscape Overview (Industry Developments Q2 2018), ‍

Section II: Novel Technologies & Trends (Industry Forecast 2019-2020), and Appendices (which feature profiles of 100 Companies, 220 Investors, 15 Biopharma, 15 IT/Tech Corporations, and 20 leading R&D Centres active in the AI for Drug Discovery space) totalling 400 pages in length, has been made available free of charge. Sections I delivers a summary of the most important recent industry events, including coverage of the most important BioPharma and IT/Tech corporations active in the space, government initiatives aiming to accelerate the dynamic of industry progress in the USA, UK, EU and Asia-Pacific region, industry-specific conferences and journalists, and a regional comparison of industry activity that summarizes which countries are currently at the forefront of activity, which ones are lagging behind, and which ones are showing evidence of rapidly increasing activity in the years to come. 

SECTION I, SECTION II, PROFILES SECTION

Section I: AISection II  provides in-depth coverage of the science and technology behind the industry, analysis of emerging subsectors and new application within the industry (including the convergence of AI with blockchain, digital medicine and Longevity technologies), and finally, a near-future forecast of industry growth and diversification from 2019 to 2020.

5b6083268b62147dccf8719d_AI for Advanced
5b61e26759281e0494de6679_to ai-p-500.png
5b6083268b62145cc0f8719c_AI for Advanced
5b608326cec62a3fdbab8258_AI for Advanced
5b648e5307daaafe991e237b_ns1-p-500.png
5b61e269774237b0f8c5073b_ai c 1-p-500.pn
5b648e5378f5c5487c26a565_nI-p-500.png
5b648e5378f5c55d4426a564_ns2-p-500.png
5b648e5307daaa0e021e237a_nc2-p-500.png
5b6468bc1bdd3fc2cf357de3_Chapter VIII-p-
5b61e26959281e4ef8de667a_ai c 9-p-500.pn
5b61f27ef40d767c5be52c80_aaaaa-p-1080.jp
adasda.png

To Get Full Access to the

Section III, please Contact Us